IFNG and neoplasm: While INCR1 serves as an inhibitory target to promote IFN-γ response and T cell activity, another cancer immunogenic lncRNA, lncRNA inducing MHC-I and immunogenicity of tumor (LIMIT), has been identified recently (150).